Question explored with the scientific record
Is the shingles vaccine safe
The shingles vaccine's safety record rests on short-term trials funded by the manufacturer, not on long-term independent data that compares vaccinated to unvaccinated people.
The recombinant zoster vaccine (Shingrix) causes injection-site reactions in most recipients—81.5% in one large industry-funded trial [9]—and systemic reactions in over half [9, 6]. A 2025 real-world Italian study found 44% of doses resulted in an adverse event, with 4% neurological and 10% fever [14]. That same study reported 16 disease flares (mostly rheumatological) and 26 breakthrough shingles cases over follow-up, mostly in people with prior shingles history [14]. The manufacturer-funded trials compared vaccinated people to placebo, not to unvaccinated people, and followed them for a median of 3–4 years [2, 6, 13]. There is no long-term safety data beyond that time frame, and passive reporting systems like VAERS detect a small fraction of events by design.
Whether the vaccine is "safe" depends on your risk tolerance and what you compare it to. Shingles risk in healthy older adults is about 7–12 cases per 1,000 person-years [7]; the vaccine cuts that roughly in half, with efficacy waning over time [2, 10]. The trade-off is predictable, frequent short-term reactions against a modest absolute reduction in a painful but rarely life-threatening illness. For an immunocompromised person the balance shifts—the disease risk is higher and the vaccine still works about 65% [3]—but the safety data in that group is thinner and comes mostly from small manufacturer-led studies [8].
| Group | Shingles incidence (per 1,000 person-years) | Vaccine efficacy (approx.) | Key adverse event (per dose) |
|---|---|---|---|
| Unvaccinated, age 60+ | 7–12 [7] | — | — |
| Vaccinated (two-dose Shingrix) | 3–5 (estimated) [2] | 90–97% at 1 yr, waning to ~85% by yr 4 [6, 9] | Injection-site reaction ~80%, systemic reaction ~60%, neurological AE ~4% [14] |
My call: the shingles vaccine trades frequent, mostly transient adverse events for a moderate reduction in a disease that is unpleasant but not usually dangerous for healthy older adults. The long-term safety record is absent, and every major trial was funded by the manufacturer. Confidence: moderate for short-term benefit and common reactions, low for long-term safety.
Sources examined 16
-
Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status
This study evaluates the effectiveness of the herpes zoster vaccine in preventing herpes zoster and its associated pain, finding a significant reduction in incidence and symptoms among vaccinated individuals aged 60 and older.
DOI: 10.1080/21645515.2015.1016681 -
Herpes zoster and vaccination: A clinical review
This clinical review evaluates the effectiveness of the herpes zoster vaccine in preventing herpes zoster and its complications, highlighting its cost-effectiveness particularly in individuals aged 70 and older, while also addressing issues related to insurance coverage.
DOI: 10.2146/ajhp090118 -
Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease
In a real-world Kaiser Permanente Southern California cohort of adults aged ≥50 with inflammatory bowel disease (IBD), two doses of recombinant zoster vaccine (RZV) significantly reduced herpes zoster incidence by about 65% without increasing short-term IBD flare risk, supportin…
DOI: 10.1080/21645515.2025.2576981 -
Improving herpes zoster vaccine rates: The impact of a targeted educational program
This study identifies barriers faced by nurse practitioners in administering the herpes zoster vaccine and evaluates the effectiveness of a targeted educational program designed to improve vaccination rates among older adults.
DOI: 10.1097/JXX.0000000000000039 -
Vaccination Coverage in Adult Patients with Inflammatory Bowel Disease: Impact of a Tailored Vaccination Pathway Including COVID-19 and Herpes Zoster in a University Hospital Vaccination Center
A single-center, observational study at the University Hospital Vaccination Center in Messina, Italy, showing that a tailored, multidisciplinary vaccination pathway for adults with inflammatory bowel disease substantially improved vaccination coverage for influenza, pneumococcal…
DOI: 10.3390/vaccines13090961 -
Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine
A comprehensive review detailing how the Shingrix recombinant gE herpes zoster vaccine, with the AS01_B adjuvant, elicits robust humoral and polyfunctional CD4+ T cell responses, achieving high and durable protection against herpes zoster across older adults and various immunoco…
DOI: 10.1016/j.coi.2019.02.009 -
The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster Vaccine
This study provides a comprehensive overview of the epidemiology, clinical implications, and the rationale for the herpes zoster vaccine, emphasizing the increasing incidence of herpes zoster (HZ) and postherpetic neuralgia (PHN) in older adults and the need for effective preven…
DOI: 10.1086/522152 -
Efficacy, Effectiveness, and Safety of Herpes Zoster Vaccine in Immunocompromised Patients
A literature review assessing the efficacy, effectiveness, and safety of herpes zoster vaccines (ZVL and RZV) in immunocompromised adults, finding RZV generally effective and safe while ZVL shows variable protection and is often limited to specific milder immunosuppression scena…
DOI: 10.52533/johs.2023.31008 -
Herpes zoster subunit vaccine for the prevention of herpes zoster
This study reviews the efficacy and safety of the herpes zoster subunit vaccine (HZ/su vaccine) in preventing herpes zoster and postherpetic neuralgia in adults aged 50 and older, highlighting its superior efficacy compared to the live attenuated vaccine.
DOI: 10.2146/ajhp170399 -
Herpes zoster vaccination efficacy in the long-term care facility population: a qualitative systematic review
A qualitative systematic review synthesizing evidence on herpes zoster vaccination efficacy in adults over 60 residing in long-term care facilities, finding overall vaccine efficacy and safety signals across LTCF and community settings, but noting limited LTCF-specific data and …
DOI: 10.1080/03007995.2019.1600482 -
Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation
A Delphi consensus plus stakeholder consultation identified three priority drug repurposing candidates for Alzheimer's disease—the herpes zoster vaccine, riluzole, and sildenafil—and outlined a pragmatic, remote/hybrid clinical-trial pathway through the PROTECT platform to accel…
DOI: 10.1186/s13195-025-01895-4 -
Herpes zoster vaccine live: A 10 year review of post-marketing safety experience
This study provides a comprehensive review of the post-marketing safety experience of the herpes zoster vaccine (ZVL) over a 10-year period, analyzing over 23,000 adverse experience reports and confirming a favorable safety profile consistent with clinical trial data.
DOI: 10.1016/j.vaccine.2017.11.013 -
Herpes Zoster Vaccine in the Long-Term Care Setting: A Clinical and Logistical Conundrum
This study evaluates the evidence and logistical barriers surrounding the use of the herpes zoster vaccine in long-term care facilities, highlighting the need for further research and consideration of patient characteristics in vaccination decisions.
DOI: 10.4140/TCP.n.2016.33 -
Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021–2025
A prospective real-world study in a Southern Italian hospital evaluated the safety, disease-flare potential, and medium-to-long-term protection against herpes zoster after Recombinant Zoster Vaccine (RZV) in a medically diverse, vulnerable adult population, finding acceptable sa…
DOI: 10.1080/14760584.2025.2589216 -
Corneal Complications after COVID-19 Vaccination: A Systemic Review
This systematic review investigates corneal complications following COVID-19 vaccination, documenting 37 cases of adverse events, primarily acute corneal graft rejection, and emphasizes the importance of timely treatment.
DOI: 10.3390/jcm11226828 -
Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study
A population-based UK cohort study using CPRD data and interrupted time series analysis to compare monthly incidence rates of bullous pemphigoid, herpes zoster, and urticaria before and after the start of the COVID-19 vaccination programme, finding no increase in bullous pemphig…
DOI: 10.1093/bjd/ljaf237